Palonosetron

Palonosetron

SCHEMBL13240607

O=C1c2cccc3c2C(CCC3)CN1[C@@H]1CN2CCC1CC2

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

HTR3A

The experimentally established mechanism targets of Palonosetron. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
HTR3A known ✓ P46098 10/20 1.00
HTR3B O95264 1/20 1.00
ADRA2A P08913 1/20 1.00
KCNE1 P15382 1/20 1.00
ADRA2C P18825 1/20 1.00
CHRM3 P20309 1/20 1.00
SLC6A4 P31645 1/20 1.00
ADRA1A P35348 1/20 1.00
HRH1 P35367 1/20 1.00
DRD3 P35462 1/20 1.00
CHRNA4 P43681 1/20 1.00
KCNQ1 P51787 1/20 1.00
KCNH2 Q12809 1/20 1.00
SCN5A Q14524 1/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Palonosetron SCHEMBL29402278 1.00 HTR3A (1.00) HTR3AHTR3BADRA2AKCNE1ADRA2C
Palonosetron SCHEMBL4058558 1.00 HTR3A (1.00) HTR3AHTR3BADRA2AKCNE1ADRA2C
Palonosetron SCHEMBL2989775 1.00 HTR3A (1.00) HTR3AHTR3BADRA2AKCNE1ADRA2C
Palonosetron SCHEMBL7782594 1.00 HTR3A (1.00) HTR3AHTR3BADRA2AKCNE1ADRA2C
Palonosetron SCHEMBL7277880 1.00 HTR3A (1.00) HTR3AHTR3BADRA2AKCNE1ADRA2C
Palonosetron SCHEMBL10066801 1.00 HTR3A (1.00) HTR3AHTR3BADRA2AKCNE1ADRA2C
Palonosetron SCHEMBL3748 1.00 HTR3A (1.00) HTR3AHTR3BADRA2AKCNE1ADRA2C
Palonosetron SCHEMBL4052980 1.00 HTR3A (1.00) HTR3AHTR3BADRA2AKCNE1ADRA2C
Palonosetron SCHEMBL3747 1.00 HTR3A (1.00) HTR3AHTR3BADRA2AKCNE1ADRA2C
Palonosetron SCHEMBL3746 1.00 HTR3A (1.00) HTR3AHTR3BADRA2AKCNE1ADRA2C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250288545-A1 NEOSTIGMINE COMBINATIONS AND COMPOSITIONS DAS-MG, INC. 2025-09-18 US disclosed
US-12390454-B2 Use and composition for protection against organophosphorus poisoning CLARENCE SMITH KATHLEEN E (US) 2025-08-19 US disclosed
US-20230172953-A1 PHYSIOLOGICALLY BALANCED INJECTABLE FORMULATIONS OF FOSNETUPITANT HELSINN HEALTHCARE SA (CH) 2023-06-08 US disclosed
US-20230172953-A1 PHYSIOLOGICALLY BALANCED INJECTABLE FORMULATIONS OF FOSNETUPITANT HELSINN HEALTHCARE SA (CH) 2023-06-08 US disclosed
US-20220409599-A1 USE AND COMPOSITION FOR PROTECTION AGAINST ORGANOPHOSPHORUS POISONING CLARENCE SMITH KATHLEEN E (US) 2022-12-29 US disclosed
US-20130079521-A1 NOVEL PALONOSETRON SALTS AND PROCESSES FOR PREPARATION AND PURIFICATION THEREOF CHEMAGIS LTD. (IL) 2013-03-28 US disclosed
US-20130079521-A1 NOVEL PALONOSETRON SALTS AND PROCESSES FOR PREPARATION AND PURIFICATION THEREOF CHEMAGIS LTD. (IL) 2013-03-28 US disclosed
US-8334388-B2 Palonosetron salts and processes for preparation and purification thereof CHEMAGIS LTD. (IL) 2012-12-18 US disclosed
US-8334388-B2 Palonosetron salts and processes for preparation and purification thereof CHEMAGIS LTD. (IL) 2012-12-18 US disclosed
US-20100174080-A1 NOVEL PALONOSETRON SALTS AND PROCESSES FOR PREPARATION AND PURIFICATION THEREOF CHEMAGIS LTD. (IL) 2010-07-08 US disclosed
US-20100174080-A1 NOVEL PALONOSETRON SALTS AND PROCESSES FOR PREPARATION AND PURIFICATION THEREOF CHEMAGIS LTD. (IL) 2010-07-08 US disclosed
WO-2008146283-A2 NOVEL PALONOSETRON SALTS AND PROCESSES FOR PREPARATION AND PURIFICATION THEREOF CHEMAGIS LTD. (IL) 2008-12-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100174080-A1 NOVEL PALONOSETRON SALTS AND PROCESSES FOR PREPARATION AND PURIFICATION THEREOF HTR3C, HTR3A, CYP3A43 HTR3A 2/4885HTR3B 4/4885ADRA2A 96/4885
US-20130079521-A1 NOVEL PALONOSETRON SALTS AND PROCESSES FOR PREPARATION AND PURIFICATION THEREOF HTR3C, HTR3A, CYP3A43 HTR3A 2/4885HTR3B 4/4885ADRA2A 105/4885
US-20230172953-A1 PHYSIOLOGICALLY BALANCED INJECTABLE FORMULATIONS OF FOSNETUPITANT FOSB, FOS, AVPR1B HTR3A 936/4885HTR3B 957/4885ADRA2A 1087/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.